ライフサイエンスコーパス: immune evasion

1 ones capable of evading immune recognition ("immune evasion").

2 y, biofilm formation, host colonization, and immune evasion.

3 ications), as tumours have multiple means of immune evasion.

4 other inflammatory mediators, tumors enhance immune evasion.

5 and that is often employed as a strategy for immune evasion.

6 umour development and progression, including immune evasion.

7 terface and can reverse important aspects of immune evasion.

8 tically relevant mechanism of cell-intrinsic immune evasion.

9 tive tissues exploit PRC2 activity to enable immune evasion.

10 ic ligand to control function and facilitate immune evasion.

11 ation can change as the virus mutates during immune evasion.

12 be critical in cancer development, including immune evasion.

13 phages, linking mRNA decay to adaptation and immune evasion.

14 ons and establishment of tumors by promoting immune evasion.

15 complex pathogen with multiple mechanisms of immune evasion.

16 obust and finely targeted mechanism of local immune evasion.

17 hocyte antitumor activity, and prevent tumor immune evasion.

18 ed activation of STAT3 drive DFTD growth and immune evasion.

19 ic potential of cancer cells promoting their immune evasion.

20 grammed cell death protein 1 (PD-1)-mediated immune evasion.

21 m formation and stability of the matrix, and immune evasion.

22 roteins has been suggested as a mechanism of immune evasion.

23 and multiple cytokines is pivotal for tumor immune evasion.

24 ubiquitin-proteasome pathway to enable viral immune evasion.

25 cations for filoviral replication and innate immune evasion.

26 A Pol I-mediated gene expression during host immune evasion.

27 ressed antigen presentation in DUX4-mediated immune evasion.

28 e involvement of complex viral mechanisms of immune evasion.

29 of M. genitalium infection, persistence, and immune evasion.

30 nces between them in polymerase function and immune evasion.

31 dictates the fate of ingested DNA in DCs for immune evasion.

32 of metastatic disease, which is dependent on immune evasion.

33 s thought to be an important driver in tumor immune evasion.

34 leukocyte antigen (HLA) loss may facilitate immune evasion.

35 are known to play important roles in tumour immune evasion.

36 evolution, including amino acid changes and immune evasion.

37 in RNA stability, efficient translation, and immune evasion.

38 two critical effectors involved in bacterial immune evasion.

39 ent and induce PD-1 signaling and associated immune evasion.

40 nduce tumor cell apoptosis or decrease tumor immune evasion.

41 repurposed for multiple functions, including immune evasion.

42 ges in receptor usage and thereby to lead to immune evasion.

43 nses, providing a mechanism that may promote immune evasion.

44 n both domains that partially contributed to immune evasion.

45 hence their likely primary role is enabling immune evasion.

46 glec-7 ligands to interfere with cancer cell immune evasion.

47 orB interactions contribute to host adaptive immune evasion.

48 s an essential role in viral replication and immune evasion.

49 sponses by M. tuberculosis may contribute to immune evasion.

50 ponses and hypothesise new modes of pathogen immune evasion.

51 ng, highlighting a novel strategy for innate immune evasion.

52 uses immune inhibitory receptors to achieve immune evasion.

53 s are known to play important roles in tumor immune evasion.

54 d EZH2 defines cancer IFN responsiveness and immune evasion.

55 ction and a potential conserved mechanism of immune evasion.

56 by both host genetic diversity and pathogen immune evasion.

57 ng transcriptional plasticity, and promoting immune evasion.

58 s often hijacked by tumors and pathogens for immune evasion.

59 eshift products that are implicated in viral immune evasion.

60 p infectivity, pathogenesis, and host innate immune evasion.

61 cells, hampered the TME switch, and enabled immune evasion.

62 e populations, suggesting a possible role in immune evasion.

63 igm of intrinsic, innate, and adaptive viral immune evasion.

64 particles, may help flavivirus survival and immune evasion.

65 sible novel targets that contribute to viral immune evasion.

66 implications for virulence and, potentially, immune evasion.

67 arions and implications for pathogenesis and immune evasion.

68 esting the glycan shield may function beyond immune evasion.

69 n hyaluronan, plays an integral role in this immune evasion.

70 plays human cell membrane proteins, enabling immune evasion.

71 and overcomes hypomethylating agent-induced immune evasion.

72 receptors to enhance replication and promote immune evasion.

73 nvasion, leading to phenotypic variation and immune evasion.

74 a mucin-like domain which may play a role in immune evasion.

75 ating GPI-anchored proteins are required for immune evasion.

76 ronment (TME) that promotes tumor growth and immune evasion.

77 oenvironment in the promotion of cancer cell immune evasion.

78 between PD-1 and its ligands supports tumor immune evasion.

79 mmune diseases and targeted by pathogens for immune evasion.

80 aling pathways mediating PD-L1-driven cancer immune evasion.

81 ch likely play a role in protein folding and immune evasion.

82 lism has emerged as a key mechanism of tumor immune-evasion.

83 importance of LpxO-dependent modification in immune evasion, 2-hydroxylation of lipid A limits the ac

84 delling of bone marrow niches can facilitate immune evasion and activation of survival pathways favou

85 The evolution of genetic mechanisms for host immune evasion and anti-malarial resistance has enabled

86 rtant S. aureus virulence factor involved in immune evasion and biofilm formation.

87 at drives this strain-to-strain variation of immune evasion and colonization is the polymorphic outer

88 Understanding the causes of immune evasion and disease progression will identify pot

89 ancer (PDAC), where it coordinately mediates immune evasion and drug resistance.

90 ur study reveals a new strategy of PRRSV for immune evasion and enhanced replication during infection

91 study unveils a novel strategy of PRRSV for immune evasion and enhanced replication during infection

92 occur particularly in antibiotic resistance, immune evasion and epithelial adhesion genes.

93 is a greater dependence on this pathway for immune evasion and hence, they exhibit more impressive p

94 l roles in cancer stem cell self-renewal and immune evasion and highlights the broad potential of tar

95 rtant for restricting HSV-1 infection, tumor immune evasion and likely also adaptive immunity.

96 altering macrophage polarization, leading to immune evasion and microbial persistence.

97 hema in mouse models of NSCLC reverses tumor immune evasion and modulates T cell exhaustion state tow

98 s reveal that PRC1 coordinates stemness with immune evasion and neoangiogenesis and point to the pote

99 ipoproteins (SLPs) fulfill critical roles in immune evasion and nutrient acquisition, but as more bac

100 s tolerance, antibiotic susceptibility, host immune evasion and overall virulence.

101 sion of Dicer is a major determinant of ZIKV immune evasion and pathogenesis and may underlie ZIKV-re

102 The HIV accessory protein Nef modulates key immune evasion and pathogenic functions, and its encodin

103 ependent of tumor cells, might contribute to immune evasion and play an essential role in bone lesion

104 recent studies have revealed roles in tumor immune evasion and poor responses to cancer immunotherap

105 d immune suppression, implicated in melanoma immune evasion and progression mediated via upregulation

106 chanistic insights into UVR-induced melanoma immune evasion and progression.See related article by Wa

107 e reactivity, thereby contributing to tumour immune evasion and promoting tumour growth in mouse mode

108 selection were observed in genes involved in immune evasion and regulation of gene expression, highli

109 ycoprotein UL148 is posited to play roles in immune evasion and regulation of viral cell tropism.

110 ial roles, ranging from metabolite uptake to immune evasion and subversion to conjugation.

111 s reveal an essential role of CpsA in innate immune evasion and suggest that LCP proteins have functi

112 studies identified p53 as a key regulator of immune evasion and suggest that TNF could be used to enh

113 The results provide insight into immune evasion and the cross-species transmission of 229

114 Here, we review the role of NLRC5 in cancer immune evasion and the future prospects for cancer resea

115 e toxin-hemolysin (CyaA) plays a key role in immune evasion and virulence of the whooping cough agent

116 ed ways to exploit these cells, facilitating immune evasion and virus dissemination.

117 accessory factor enhances viral infectivity, immune evasion, and AIDS progression.

118 structural support, metabolism, replication, immune evasion, and disease severity.

119 has been shown to be critical for survival, immune evasion, and escape, while the importance of cata

120 structural basis of resistance to apoptosis, immune evasion, and loss of cell junctions seen in H. py

121 oles for NSP1-1 in RVB host species tropism, immune evasion, and pathogenesis.

122 ted roles for NSP1-1 in RVB species tropism, immune evasion, and pathogenesis.IMPORTANCE While specie

123 eoplasticity, invasiveness, chemoresistance, immune evasion, and ultimately to poor prognosis of canc

124 Here we demonstrate that stemness and immune evasion are closely intertwined in AML.

125 Genomic instability and immune evasion are hallmarks of cancer.

126 ations suggest that bacterial metabolism and immune evasion are linked by virtue of this moonlighting

127 CD47 has been shown to mediate immune evasion, as the CD47-SIRPalpha axis prevents phag

128 The mechanisms that enable immune evasion at metastatic sites are poorly understood

129 that functions in flavivirus replication and immune evasion but is absent from the virion.

130 presents a strategy that tumor cells use for immune evasion, but the underlying mechanisms are unclea

131 . gondii-host interaction, pathogenesis, and immune evasion, but their exact roles remain unknown.

132 putative translesion DNA polymerase to host immune evasion by antigenic variation.

133 iological therapy, improved understanding of immune evasion by cancer cells and the discovery of sele

134 IDO1, KMO, KYNU) that play a pivotal role in immune evasion by certain other microbial pathogens by d

135 re we describe a means of anticipating HIV-1 immune evasion by dividing Env into N-glycan microdomain

136 d that Pfs47 serves as a "key" that mediates immune evasion by interacting with a mosquito receptor "

137 s diverse host-associated signals to promote immune evasion by masking of a major pathogen-associated

138 Our studies revealed a strategy of immune evasion by MNV via the induction of a CD8(+) T ce

139 s, we show that tumor-secreted Gal1 mediates immune evasion by preventing T cell migration into the t

140 meostasis, but they also contribute to tumor immune evasion by promoting a suppressive tumor microenv

141 mia cells are dependent upon calcineurin for immune evasion by restricting the regulation of proinfla

142 r enhanced autophagy or lysosome function in immune evasion by selective targeting of MHC-I molecules

143 t a potential therapeutic target to overcome immune evasion by tumour cells.

144 Importantly, this mechanism of immune evasion can be circumvented with small-molecule C

145 Mechanisms of immune evasion can involve abrogation of leukemia cell r

146 emonstrate that blocking leukocidin-mediated immune evasion can promote host protection against S. au

147 on, modulation of host gene expression, host immune evasion, cellular survival, and cellular transfor

148 vation of a conserved prophage harboring the immune evasion cluster (IEC).

149 ents a continuous, supplemental mechanism of immune evasion co-opted by tumors to evade antitumor imm

150 ted with metastatic aggressiveness including immune evasion, collective dissemination of tumor cells,

151 ission experiments, a proposed mechanism for immune evasion consists of increased avidity to host cel

152 This mechanisms of immune evasion could have implications for treatment of

153 ipulate the IL-10 response as a mechanism of immune evasion during chronic systemic and biofilm model

154 -risk HPV E7 may contribute to virus-induced immune evasion during HPV persistence.

155 acellular signaling molecule responsible for immune evasion during leukemia progression and raises th

156 However, the mechanisms of immune evasion during leukemia progression remain poorly

157 t al. (2017) determine that norovirus innate immune evasion enables infection of intestinal epithelia

158 icity, pathogenicity, molecular mimicry, and immune evasion, expanding our understanding of host-micr

159 ealing a new function for this protein as an immune evasion factor.

160 al replication and is the major viral innate immune evasion factor.

161 tify EBV-encoded miR-BART16 as a novel viral immune-evasion factor that interferes with the type I IF

162 ll-down conformation potentially facilitates immune evasion from RBD-up binding antibody.

163 We conclude that FnBPB provides a dual immune-evasion function that captures histones and preve

164 ur study provides molecular understanding of immune evasion functions of ZIKV, which may guide vaccin

165 immune responses is attributable to the many immune evasion genes encoded within its genome.

166 onment and heterogeneous mechanisms of tumor immune evasion has also expanded.

167 he tumor microenvironment that contribute to immune evasion has become an important area of research.

168 PD-L1 expression and contributing to cancer immune evasion, highlighting the potential for repurposi

169 m neutralization as a potential mechanism of immune evasion.IMPORTANCE HSV-1 causes lifelong infectio

170 t and replication in the nucleus facilitates immune evasion.IMPORTANCE We used intracellular nanobodi

171 Their findings provide a new mechanism for immune evasion in cancer and highlight the pathogenic ef

172 rosine kinases and as receptors that mediate immune evasion in cancer progression.

173 new strategies for overcoming PD-L1-mediated immune evasion in cancer.

174 A greater understanding of the processes of immune evasion in chronic infections and malignant tumor

175 Our findings demonstrate a mechanism of immune evasion in IDH-MUT gliomas and suggest that speci

176 tutes a tumor-intrinsic mechanism underlying immune evasion in MIBC.

177 ) receptor and its ligand (PD-L1) facilitate immune evasion in multiple myeloma (MM).

178 Furthermore, this variant displays robust immune evasion in nonhuman primate and human serum sampl

179 These findings identify a new modality for immune evasion in PDA that depends on IL1beta production

180 ide additional evidence of the importance of immune evasion in PMBL (CIITA, CD58, B2M, CD274, and PDC

181 to altered nutrient requirements and promote immune evasion in the context of a heterogeneous lung tu

182 ells (MDSC) represent a primary mechanism of immune evasion in tumors and have emerged as a major obs

183 ys, including cell signaling, cell cycle and immune evasion, in their development.

184 onment in nude mice, exhibited signatures of immune evasion, increased stemness, increased calcium si

185 Immune evasion is a hallmark of cancer.

186 Immune evasion is a major obstacle for cancer treatment.

187 Cancer immune evasion is achieved through multiple layers of im

188 Immune evasion is critical for viral persistence.

189 Viral immune evasion is currently understood to focus on defle

190 nity in protection against HCV infection and immune evasion is only partially understood.

191 infection, suggesting that CpsY function in immune evasion is specific to the human host.

192 le this flexibility is thought to facilitate immune evasion, it may also reflect the heterogeneity of

193 s an important role in virus replication and immune evasion, making it an attractive target for antiv

194 associated severity of HFMD, suggesting that immune evasion may be an indirect driver for virulence (

195 Our findings reveal an immune evasion mechanism and have implications for the d

196 During evolution, this novel viral immune evasion mechanism could have prompted the develop

197 This immune evasion mechanism dampens the host immune respons

198 the tumor microenvironment (TME) is a major immune evasion mechanism in some patients with cancer, a

199 y NK cells, unravels a fundamental new viral immune evasion mechanism, and demonstrates how this forc

200 Thus, cancer methionine consumption is an immune evasion mechanism, and targeting cancer methionin

201 erum survival, but phase variation can be an immune evasion mechanism, and thus, this modification ma

202 nd that proteolysis of galectin-3 is a novel immune evasion mechanism.

203 lpP inactivation may function as a potential immune evasion mechanism.

204 I interferon receptor IFNAR1 chain as a new immune-evasion mechanism in colorectal cancers.

205 DUB activity of HSV1 VP1-2 is a major viral immune-evasion mechanism in the brain.

206 These results unveil an immune-evasion mechanism mediated by the esophageal glan

207 aches that will help dissect M. tuberculosis immune evasion mechanisms and devise strategies to bypas

208 te, our work expands knowledge of the innate immune evasion mechanisms associated with NEMO cleavage

209 HCC ecosystem provides deeper insights into immune evasion mechanisms associated with tumor relapse.

210 driven prosurvival, genetic instability, and immune evasion mechanisms in DLBCL and provide preclinic

211 Below we discuss immune evasion mechanisms in leukemia and lymphoma, high

212 and interaction analyses revealed potential immune evasion mechanisms in recurrent tumor cells that

213 Observations: Immune evasion mechanisms of these viral infections have

214 ures, owing to lack of power or to efficient immune evasion mechanisms that are active early during t

215 , however, are well known for their numerous immune evasion mechanisms that limit the true potential

216 This study suggests that EAV employs complex immune evasion mechanisms that warrant further investiga

217 -receptor repertoires identified novel tumor immune evasion mechanisms through genetic alterations.

218 virulence determinants, biofilm growth, and immune evasion mechanisms, comparatively little is known

219 spond, suggesting existence of complementary immune evasion mechanisms.

220 tissues is associated with colonization and immune evasion mechanisms.

221 aled that NLRC5 is a major target for cancer immune evasion mechanisms.

222 standing of the role of HCV in inflammation, immune evasion, metabolic disorders, liver pathogeneses,

223 Other strategies include immune evasion, microbiome-modifying therapies, and the

224 We recovered the known immune evasion molecules PD-L1 and CD47, and confirmed t

225 V lesions persist because of virally encoded immune evasion molecules that inhibit antiviral response

226 g, which suggests the presence of phagosomal immune evasion molecules.

227 nctions, despite the presence of CMV-encoded immune evasion molecules.

228 sly found that cHLs have a genetic basis for immune evasion: near-uniform copy number alterations of

229 n mechanistic differences in replication and immune evasion observed for MARV and EBOV.

230 the skin microenvironment, which may promote immune evasion of oncogenic cells and drive melanoma ini

231 s that similar phenomena could contribute to immune evasion of other viruses.

232 y involved in the vascular sequestration and immune evasion of parasites in malaria.

233 Selective immune evasion of PR-positive tumors may be one explanat

234 mmune response in asymptomatic subjects, the immune evasion of severe acute respiratory syndrome coro

235 PD-L1 on tumor cells is sufficient for tumor immune evasion or simply correlates with an inflamed tum

236 evated in absence of NRF2 and coincided with immune evasion parameters in human melanoma datasets.

237 are well characterized and knowledge of the immune evasion pathways exploited by these malignancies

238 t underlying mechanism that leads to a tumor immune evasion phenotype in both humans and mice.

239 a pro-oncogenic lncRNA that mediates cancer immune evasion, pointing to a new target for immune pote

240 intra-tumoral heterogeneity, metastasis, and immune evasion, presenting transformative opportunities

241 ed in the structural strength, motility, and immune evasion properties of the infective sporozoites.

242 P, may provide the sporozoites not only with immune evasion properties, but also with lubricating cap

243 Vaccinia virus (VACV) encodes an innate immune evasion protein, E3, which contains an N-terminal

244 s of the EAP family of Staphylococcus aureus immune evasion proteins potently inhibit the neutrophil

245 mRNA encoding for reprogramming factors and immune evasion proteins.

246 ed frequency-dependent selection process for immune evasion, raising issues for vaccine development.

247 in RAS, PIK3CA, SWI/SNF-complex genes and in immune evasion regulators.

248 refore, it is essential that M. tuberculosis immune evasion-related pathogen virulence strategies are

249 nd mechanisms underlying chronic illness and immune evasion remain elusive.

250 esponses, yet the complex mechanisms driving immune evasion remain poorly understood.

251 and the impact of this process on successful immune evasion, remain unclear.

252 epigenomic changes in tumor progression and immune evasion, respectively.

253 protein and a novel mechanism for DNA virus immune evasion, resulting in increased CD8(+) T-cell mem

254 Immune evasion strategies adopted by Leishmania donovani

255 our understanding of viral pathogenesis and immune evasion strategies but also of the immune signali

256 We discuss immune evasion strategies during early infection, from d

257 onses' which exploit host signals to trigger immune evasion strategies that protect them against immi

258 proteins (Env), gp120 and gp41, have evolved immune evasion strategies that render the elicitation of

259 Unfortunately, many cancer cells use immune evasion strategies to avoid their eradication by

260 em against phagocytic killing, and activates immune evasion strategies.

261 racellular environment, and its multifaceted immune evasion strategies.

262 serves as a critical component of the cancer immune evasion strategy and can be an effective immunoth

263 ); our data reveal that IL-36 overcomes this immune evasion strategy by increasing cellular sensitivi

264 of MHC class I has been described as a major immune evasion strategy in many cancers.

265 A unique gonococcal immune evasion strategy involves capping of lipooligosac

266 Why HIV-1 does not employ this potential immune evasion strategy is not fully understood.

267 ere found to be downregulated, suggesting an immune evasion strategy of A. invadans in establishing t

268 These results identify an unanticipated immune evasion strategy of Mtb in the BM that controls t

269 istribution and spectrum of activity of this immune evasion strategy remain largely unknown.

270 ce factor, and highlights a potential innate immune evasion strategy that may be employed by other ba

271 In conclusion, using a viral immune evasion strategy that shows broad immune-ablating

272 his represents a sophisticated but efficient immune evasion strategy to allow transfer of progeny vir

273 on and that PD-L1 expression is an important immune evasion strategy used by KSHV for its survival an

274 Neisseria gonorrhoeae deploys a unique immune evasion strategy wherein the lacto-N-neotetraose

275 sustain a highly effective and paradigmatic immune evasion strategy.

276 hese results highlight a novel MCMV-mediated immune evasion strategy.

277 This study characterizes an immune-evasion strategy used by malaria parasites and hi

278 These immune evasion tactics blunt the effectiveness of immuni

279 e we describe a novel mechanism of CLL tumor immune evasion that is independent of T-cell exhaustion,

280 Brazil directs a passive strategy of innate immune evasion that is reminiscent of a stealth virus.

281 ptive binK alleles promoted colonization and immune evasion that were mediated by cell-associated mat

282 n also fuels inflammation and supports tumor immune evasion, thereby serving as an immunological driv

283 role of LANA to modulate its expression and immune evasion through formation of G-quadruplexes in it

284 role for tumour-expressed CD24 in promoting immune evasion through its interaction with the inhibito

285 nic enzyme activation-induced deaminase, and immune evasion through major histocompatibility complex

286 Immune evasion through membrane remodeling is a hallmark

287 e many tumor-promoting functions and promote immune evasion through multiple mechanisms, but as yet,

288 the signaling adaptors MYD88 and CD79B, and immune evasion through mutation of antigen-presenting ge

289 nctional mutants in vivo to biofilm-mediated immune evasion, thus to mechanisms that are specific to

290 of cancer, tumor cells employ mechanisms of immune evasion to avoid elimination by protective CD4(+)

291 paB axis can be exploited to overcome cancer immune evasion triggered by conventional or targeted the

292 suppressor cells (MDSCs) are key players in immune evasion, tumor progression and metastasis.

293 ant finding, as it highlights a mechanism of immune evasion utilized by HCMV to decrease the expressi

294 We describe a novel mechanism of HSV-1 immune evasion via ICP22-dependent downregulation of the

295 s provide new insights into the mechanism of immune evasion via m(6)A modification of viral RNAs.

296 ains, as well as investigate glycan-mediated immune evasion via molecular mimicry.

297 es that bind PIMMS43 interfere with parasite immune evasion when ingested with the infectious blood m

298 ung cancers that produces multiple routes to immune evasion, which are clinically relevant and foreca

299 berrant upregulation of proteins involved in immune evasion, which informed identification of potenti

300 facilitated colonisation, dissemination and immune evasion within the novel finch host.